prulifloxacin has been researched along with Urinary Tract Infections in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Rawashdah, S; Al Salhi, Y; Carbone, A; Coppola, G; Fuschi, A; Leto, A; Maruccia, S; Maurizi, A; Mele, R; Palleschi, G; Pastore, AL; Velotti, G; Zanello, PP | 1 |
| Falagas, ME; Karageorgopoulos, DE; Maraki, S; Samonis, G; Schito, GC; Vatopoulos, AC | 1 |
| Bini, V; Costantini, E; Di Biase, M; Frumenzio, E; Giovannozzi, S; Maglia, D; Salvini, E | 1 |
| Bini, V; Cicalese, A; Costantini, E; Filocamo, MT; Lazzeri, M; Li Marzi, V; Salvini, E; Zucchi, A | 1 |
| Bartoletti, R; Boddi, V; Cai, T; Mazzoli, S; Mondaini, N; Nesi, G | 1 |
| De Vecchi, E; Drago, L; Mattina, R; Nicola, L | 1 |
| Falagas, ME; Polyzos, KA; Rafailidis, PI; Sgouros, K | 1 |
| Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G | 1 |
| Keam, SJ; Perry, CM | 1 |
| Carmignani, G; De Rose, AF; Dionisio, P; Olivieri, L; Rosignoli, MT; Salvatori, E | 1 |
| Gualco, L; Marchese, A; Schito, AM; Schito, GC | 1 |
| Esposito, S; Ianniello, F; Leone, S; Noviello, S | 1 |
| Ida, T; Kariyama, R; Kato, Y; Kumon, H; Maebashi, K; Mikuniya, T; Monden, K | 1 |
| Adachi, T; Honmura, T; Matsuda, M; Nishimura, I; Nishino, T; Okawa, Y; Ozaki, M; Tomii, Y; Yamaguchi, R | 1 |
| Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
1 review(s) available for prulifloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Urinary Tract Infections | 2011 |
6 trial(s) available for prulifloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation.
Topics: Acetylcysteine; Aged; Anti-Bacterial Agents; Antibiosis; Antibiotic Prophylaxis; Bacterial Adhesion; Dioxolanes; Female; Fluoroquinolones; Fruit; Humans; Incidence; Male; Mannose; Middle Aged; Morinda; Piperazines; Plant Extracts; Prospective Studies; Urinary Tract Infections; Urodynamics | 2017 |
Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Female; Fluoroquinolones; Fosfomycin; Humans; Middle Aged; Piperazines; Recurrence; Treatment Outcome; Urinary Tract Infections | 2014 |
14-day prulifloxacin treatment of acute uncomplicated cystitis in women with recurrent urinary tract infections: a prospective, open-label, pilot trial with 6-month follow-up.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Cystitis; Dioxolanes; Female; Fluoroquinolones; Follow-Up Studies; Humans; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome; Urinary Tract Infections; Urine; Vagina; Young Adult | 2009 |
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Disk Diffusion Antimicrobial Tests; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Respiratory Tract Infections; Treatment Outcome; Urinary Tract Infections; Young Adult | 2012 |
Prulifloxacin.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Clavulanic Acid; Dioxolanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Italy; Molecular Structure; New Zealand; Pefloxacin; Piperazines; Prodrugs; Quinolones; Urinary Tract Infections | 2004 |
Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome; Urinary Tract Infections | 2005 |
8 other study(ies) available for prulifloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Community-Acquired Infections; Dioxolanes; Female; Fluoroquinolones; Greece; Humans; Male; Microbial Sensitivity Tests; Piperazines; Prospective Studies; Respiratory Tract Infections; Urinary Tract Infections | 2013 |
Role of phytotherapy associated with antibiotic prophylaxis in female patients with recurrent urinary tract infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Combined Modality Therapy; Dioxolanes; Female; Fluoroquinolones; Fosfomycin; Humans; Middle Aged; Phytotherapy; Piperazines; Recurrence; Retrospective Studies; Urinary Tract Infections | 2013 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Klebsiella; Klebsiella Infections; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Respiratory Tract Infections; Selection, Genetic; Urinary Tract Infections | 2010 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hemolysin Proteins; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Ultraviolet Rays; Urinary Tract Infections | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Catheters, Indwelling; Dioxolanes; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Fosfomycin; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Piperazines; Polyethylene; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rats; Urinary Catheterization; Urinary Tract Infections | 2007 |
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Area Under Curve; Dioxolanes; Escherichia coli Infections; Fluoroquinolones; Half-Life; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Urinary Tract Infections | 1996 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |